Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Free Cash Flow: 2023-2025

Historic Free Cash Flow for Zenas BioPharma (ZBIO) over the last 2 years, with Sep 2025 value amounting to -$41.1 million.

  • Zenas BioPharma's Free Cash Flow fell 32.41% to -$41.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$158.6 million, marking a year-over-year decrease of 64.19%. This contributed to the annual value of -$119.8 million for FY2024, which is 292.21% down from last year.
  • As of Q3 2025, Zenas BioPharma's Free Cash Flow stood at -$41.1 million, which was up 1.48% from -$41.7 million recorded in Q2 2025.
  • In the past 5 years, Zenas BioPharma's Free Cash Flow registered a high of -$15.4 million during Q4 2023, and its lowest value of -$41.7 million during Q2 2025.
  • For the 3-year period, Zenas BioPharma's Free Cash Flow averaged around -$31.9 million, with its median value being -$34.1 million (2024).
  • Data for Zenas BioPharma's Free Cash Flow shows a maximum YoY tumbled of 150.83% (in 2024) over the last 5 years.
  • Over the past 3 years, Zenas BioPharma's Free Cash Flow (Quarterly) stood at -$15.4 million in 2023, then crashed by 150.83% to -$38.6 million in 2024, then crashed by 32.41% to -$41.1 million in 2025.
  • Its last three reported values are -$41.1 million in Q3 2025, -$41.7 million for Q2 2025, and -$37.1 million during Q1 2025.